1. High MMP-26 expression in glioma is correlated with poor clinical outcome of patients.
- Author
-
Guo, Jian-Gui, Guo, ChENg-ChENg, He, ZhEN-Qiang, Cai, Xiu-Yu, and Mou, Yong-Gao
- Subjects
MATRIX metalloproteinases ,GLIOMAS ,IMMUNOHISTOCHEMISTRY ,NEOVASCULARIZATION ,METASTASIS - Abstract
To date the management of glioma remains a great challenge in cancer therapy worldwide. The identification of novel diagnostic and therapeutic methods is required. Although there is data indicating that matrix metalloproteinase (MMP)-26 serves an important role in many human cancer types, its clinical significance in glioma remains uncertain. The present study aimed to evaluate MMP-26 expression in human astrocytic glioma specimens, and investigate its role and significance in the progression of astrocytic glioma. Immunohistochemistry was performed to assess MMP-26 expression in astrocytic glioma tissues. The levels of MMP-26 expression and its relevance to the clinicopathological features and prognostic factors in patients with astrocytic glioma patients were then investigated. The results demonstrated that MMP-26 expression was significantly assocaited with the World Health Organization grade (P<0.05). Additionally, it was identified that MMP-26 expression was an effective predictor of the overall survival of patients with astrocytic glioma (P<0.05). Analyses of univariate and multivariate Cox regression confirmed that MMP-26 expression was an independent factor for evaluating the prognosis of astrocytic glioma patients (P<0.05). The current results support that MMP-26 may be a novel indicator of diagnosis and an independent factor for evaluating prognosis in patients with glioma. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF